Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00558272 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 139
- Enrollment target
NCT00558272 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 139 participants.
The verdict
NCT00558272, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 139 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of AZD0530 on subjects with breast cancer or prostate cancer with metastatic bone disease in comparison to zoledronic acid.
Interventions
- DRUG Zoledronic Acid
- DRUG AZD0530
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2008-02 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00558272
The ClinicalTrials.gov registry entry for NCT00558272 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zoledronic Acid is the first listed.
NCT00558272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00558272 about?
NCT00558272 is a clinical study titled "Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease". The purpose of this study is to determine the effect of AZD0530 on subjects with breast cancer or prostate cancer with metastatic bone disease in comparison to zoledronic acid.
What is the current status of trial NCT00558272?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 139 participants. The study started on 2008-02. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00558272?
The interventions under investigation include: Zoledronic Acid (DRUG), AZD0530 (DRUG).
Who is sponsoring clinical trial NCT00558272?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.